2. Academic Validation
  3. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia

Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia

  • J Med Chem. 2009 Nov 12;52(21):6531-4. doi: 10.1021/jm901042m.
Benjamin E Blass 1,  Andrew Fensome,  Eugene Trybulski,  Ronald Magolda,  Stephen J Gardell,  Kun Liu,  Manoj Samuel,  Irene Feingold,  Christine Huselton,  Chris M Jackson,  Laurent Djandjighian,  Douglas Ho,  James Hennan,  John M Janusz
Affiliations

Affiliation

  • 1 Chemical Sciences, Wyeth Research, Collegeville, Pennsylvania 19426, USA. blassb@wyeth.com
PMID: 19888755 DOI: 10.1021/jm901042m
Abstract

Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.

Figures
Products